Adage Capital Partners’s Jazz Pharmaceuticals JAZZ Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-548,000
| Closed | -$93.2M | – | 1018 |
|
|
2025
Q4 | $93.2M | Buy |
548,000
+395,000
| +258% | +$60.6M | 0.14% | 139 |
|
|
2025
Q3 | $20.2M | Buy |
153,000
+17,963
| +13% | +$2.15M | 0.03% | 466 |
|
|
2025
Q2 | $14.3M | Buy |
135,037
+122,037
| +939% | +$13.3M | 0.02% | 529 |
|
|
2025
Q1 | $1.61M | Buy |
+13,000
| New | +$1.7M | ﹤0.01% | 773 |
|
|
2022
Q4 | – | Sell |
-114,260
| Closed | -$15.2M | – | 1014 |
|
|
2022
Q3 | $15.2M | Sell |
114,260
-610,740
| -84% | -$92.9M | 0.04% | 508 |
|
|
2022
Q2 | $113M | Buy |
725,000
+75,000
| +12% | +$11.5M | 0.26% | 81 |
|
|
2022
Q1 | $101M | Sell |
650,000
-100,000
| -13% | -$14.5M | 0.19% | 112 |
|
|
2021
Q4 | $95.5M | Buy |
750,000
+242,606
| +48% | +$31.9M | 0.17% | 126 |
|
|
2021
Q3 | $66.1M | Buy |
507,394
+200,000
| +65% | +$30.2M | 0.13% | 164 |
|
|
2021
Q2 | $54.6M | Sell |
307,394
-292,606
| -49% | -$50.7M | 0.11% | 198 |
|
|
2021
Q1 | $98.6M | Buy |
600,000
+285,000
| +90% | +$46.9M | 0.2% | 113 |
|
|
2020
Q4 | $52M | Buy |
315,000
+90,000
| +40% | +$13.4M | 0.11% | 196 |
|
|
2020
Q3 | $32.1M | Hold |
225,000
| – | – | 0.08% | 263 |
|
|
2020
Q2 | $24.8M | Buy |
+225,000
| New | +$24.9M | 0.06% | 331 |
|
|
2018
Q3 | – | Sell |
-193,000
| Closed | -$33.3M | – | 734 |
|
|
2018
Q2 | $33.3M | Sell |
193,000
-156,189
| -45% | -$25.5M | 0.08% | 288 |
|
|
2018
Q1 | $52.7M | Sell |
349,189
-119,186
| -25% | -$17.5M | 0.12% | 210 |
|
|
2017
Q4 | $63.1M | Buy |
468,375
+143,375
| +44% | +$19.9M | 0.14% | 181 |
|
|
2017
Q3 | $47.5M | Sell |
325,000
-325,000
| -50% | -$49.2M | 0.12% | 233 |
|
|
2017
Q2 | $101M | Sell |
650,000
-575,000
| -47% | -$87.9M | 0.25% | 109 |
|
|
2017
Q1 | $178M | Buy |
1,225,000
+500,000
| +69% | +$65.1M | 0.45% | 49 |
|
|
2016
Q4 | $79M | Buy |
725,000
+475,000
| +190% | +$52.9M | 0.22% | 131 |
|
|
2016
Q3 | $30.4M | Buy |
+250,000
| New | +$33.7M | 0.08% | 313 |
|
|
2016
Q2 | – | Sell |
-50,000
| Closed | -$6.53M | – | 703 |
|
|
2016
Q1 | $6.53M | Buy |
+50,000
| New | +$6.22M | 0.02% | 580 |
|
|
2014
Q4 | – | Sell |
-145,000
| Closed | -$23.3M | – | 741 |
|
|
2014
Q3 | $23.3M | Buy |
145,000
+3,000
| +2% | +$461K | 0.06% | 360 |
|
|
2014
Q2 | $20.9M | Buy |
142,000
+42,000
| +42% | +$5.82M | 0.05% | 388 |
|
|
2014
Q1 | $13.9M | Buy |
100,000
+45,000
| +82% | +$6.77M | 0.04% | 451 |
|
|
2013
Q4 | $6.96M | Buy |
55,000
+30,000
| +120% | +$3.1M | 0.02% | 561 |
|
|
2013
Q3 | $2.3M | Sell |
25,000
-310,000
| -93% | -$25M | 0.01% | 637 |
|
|
2013
Q2 | $23M | Buy |
+335,000
| New | +$20.5M | 0.07% | 329 |
|
Other funds holding JAZZ
VPM
VCM
EC
Adage Capital Partners's JAZZ Position: Q1 2026 in Review
Adage Capital Partners sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2026, closing a stake of 548,000 shares — an estimated $93.2M sold.
Adage Capital Partners first reported a position in JAZZ in Q2 2013 and held it in 29 quarters. The position peaked at $178M in Q1 2017. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.
- Adage Capital Partners reported no remaining Jazz Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
- Adage Capital Partners sold 548,000 Jazz Pharmaceuticals shares in Q1 2026, an estimated $93.2M.
- Adage Capital Partners first reported a position in Jazz Pharmaceuticals in Q2 2013 and held it in 29 quarters.
- Adage Capital Partners's Jazz Pharmaceuticals position peaked at $178M in Q1 2017.
- 570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.
Based on Adage Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.